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Of 35 million people currently living with HIV world-
wide, around 4 million (12%) have chronic hepatitis C.
Although intravenous drug users are overepresented
within the HIV-HCV coinfected population, recent out-
breaks of acute hepatitis C among homosexual men
highlight that HCV can also be transmitted efficiently
by sex. Progression to cirrhosis, liver insufficiency and
hepatocellular carcinoma occurs in coinfected patients
more rapidly than in HCV-monoinfected individuals.
Therefore, antiviral therapy for hepatitis C has become a
priority in this population.
Classical therapy based on interferon provided low rates
of HCV cure in the HIV setting. Although the advent of
first generation direct-acting antivirals boceprevir and tela-
previr increased sustained virological response rates, it was
at the cost of a high rate of side effects and significant
drug interactions with antiretrovirals.
The recent approval of sofosbuvir and simeprevir has
revolutionized the field, as these agents in combination with
peginterferon-ribavirin provide high rates of cure without
adding noticeable toxicity and drug interactions and with
shorter treatment duration. Moreover, sofosbuvir plus riba-
virin alone provides cure to most patients with HCV geno-
types 2 and 3. On the other hand, the combination of
sofosbuvir plus simeprevir may cure most patients infected
with HCV genotypes 1 or 4 ineligible for interferon.
All these unprecedent successes, however, are currently
challenged by the very high cost of these medications.
Unless their price goes down or new oral anti-HCV
agents expected to be approved soon (i.e., daclatasvir
and/or faldaprevir) are marketed at lower prices, it is
unlikely a rapid widespread use of antiviral therapy for
chronic hepatitis C in coinfected patients. The risk is
further marginalization of groups and persons.
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